Preactivation-Discovery and Biological Effects of Novel Chemotherapeutic Agents
- 19 Downloads
As an immunologist, my research interests had been focused on immunotherapy of cancer involving monoclonal antibodies as a mode of drug delivery and cytokines as therapeutic agents. I had no real interest or in-depth understanding of photobiology until September 1986, when I joined the Baylor Research Foundation (now Baylor Research Institute) where several photobiology related projects were already in progress. In one of these projects lead by Dr. Lester Matthews, it was demonstrated that in vivo chloroquine resistant parasitemia caused by P. berghei (resistant to at least three daily doses of 0.4 mg/kg of chloroquine) could be significantly reduced when treated with hematoporphyrin derivative (HPD) prior to chloroquine injection.1 Therefore, the following question was asked; if HPD plus chloroquine = death of the parasite, then what other compound (say X) plus HPD will induce death in tumor cells? Finding the answer to this question was one of my research projects, and it involved the determination of the dark toxicity of HPD in the presence of compound X against cultured tumor cells. This was the beginning of my inculcation into the field of photo-dynamic therapy.
KeywordsPhotodynamic Therapy Simian Immunodeficiency Virus Human Peripheral Blood Mononuclear Cell Tiaprofenic Acid Culture Tumor Cell
Unable to display preview. Download preview PDF.
- 4.Sieber F. Marrow purging by merocyanine 540 mediated photolysis. Bone Marrow Transplantation. Proceedings of the First International Workshop on Bone Marrow Purging 1987; 2:(Suppl. 2)29–33.Google Scholar
- 8.Gulliya KS. An in vitro model of autologous bone marrow purging for multiple myeloma and lung carcinoma cells by laser photo-radiation therapy. Cancer J 1989; 2: 378–82.Google Scholar
- 9.Gulliya KS, Battaglino M. Breast cancer and laser photoradiation therapy: An in vitro model of autologous bone marrow purging. In: Gross S, Gee AP, Worthington-White DA, eds. Prog Clin Biol Res. New York: Wiley-Liss, 1989: 133: 103–107.Google Scholar
- 11.van Lier JE, Spikes JD. The chemistry, photophysics and photosensitizing properties of of phthalocyanines. In: Bock G, Harnett Wiley S, eds. Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use. Chichester: Ciba Foundation, 1989: 146: 17–26.Google Scholar
- 16.Longo DL. Lung Cancer: The (red) light at the end of tunnel? Abstract and commentary. Clinical Oncology Alert 1993; 8: 91–92.Google Scholar
- 17.Chang Po-H, Pervaiz S, Battaglino M et al. Synergistic effect of preactivated photofrin-II and tamoxifen in killing retrofibroma pseudomyxoma and breast cancer cells. Eur J Cancer 1991; 28: 1034–39.Google Scholar
- 27.Blough HA, Tiffany JM, eds. Cell Membranes and Viral Envelopes. New York: Academic Press, 1980; 2: 459–518.Google Scholar
- 29.Chanh TC, Allan JS, Pervaiz S. Preactivated merocyanine 540 inactivates HIV-1 and SIV: Potential therapeutic and blood banking applications. J AIDS 1992; 5: 188–95.Google Scholar
- 36.Klein G. Tumor-specific transplantation antigens: G. H. A Clowes memorial lecture (Review).Cancer Res 1968; 28: 625–35.Google Scholar